Nightfood Holdings Inc. (OTCQB: NGTF) announced that its subsidiary, TechForce Robotics, has successfully completed Phase 1 objectives under its joint development agreement with Oncotelic Therapeutics (OTCQB: OTLC), highlighted by the initial deployment of LIM-E, an autonomous laboratory support robot. This deployment marks TechForce’s first expansion into pharmaceutical and laboratory automation and validates the adaptability of its AI-enhanced robotics platform beyond hospitality and service-industry applications into life sciences and pharmaceutical environments.
TechForce said the deployment completed the initial operational goals established under the companies’ April 2026 collaboration agreement and will provide operational data and workflow insights to support future automation initiatives. The companies plan to continue evaluating opportunities in laboratory logistics, manufacturing support, AI-enhanced workflows and other automation applications, while Nightfood views healthcare, life sciences and pharmaceutical manufacturing as significant long-term growth markets for its Robotics-as-a-Service platform.
The deployment of LIM-E represents a strategic milestone for Nightfood Holdings, as it diversifies the company’s robotics applications beyond its core hospitality focus. By entering the pharmaceutical sector, Nightfood positions itself to capture a share of the growing demand for automation in drug manufacturing and laboratory processes. This move aligns with broader industry trends where pharmaceutical companies are increasingly adopting robotics to improve efficiency, reduce errors, and enhance workflow consistency.
For Oncotelic Therapeutics, a clinical-stage biopharmaceutical company focused on oncology and immunotherapy, the collaboration with TechForce could streamline laboratory operations and support its pipeline of therapeutic candidates. The successful Phase 1 deployment provides a foundation for scaling automation across Oncotelic’s facilities, potentially accelerating research and development timelines.
The implications of this announcement extend beyond the two companies. As TechForce’s AI-enhanced robotics platform proves its versatility in a regulated environment like pharmaceuticals, it opens the door for similar deployments in other life science settings, such as biotech laboratories and medical device manufacturing. Nightfood’s Robotics-as-a-Service model also offers a cost-effective entry point for companies that may not have the capital to purchase expensive automation systems outright.
Investors should note that Nightfood Holdings is positioning itself in a long-term growth market. The pharmaceutical automation sector is expected to expand as drug manufacturers seek to modernize facilities and comply with stringent quality standards. TechForce’s successful deployment of LIM-E serves as a proof of concept that could attract additional partnerships and contracts in the future.
For more information about Nightfood Holdings, visit www.nightfoodholdings.com. For more about Oncotelic Therapeutics, visit www.oncotelic.com. The full press release is available at https://ibn.fm/RFkfL.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Nightfood Subsidiary TechForce Deploys Autonomous Lab Robot in Pharmaceutical Automation Milestone.